Prescription medicine
Aflibercept-mrbb Brand names: Ahzantive
Aflibercept-mrbb (Ahzantive) is a prescription medicine with an FDA approval on record since 2024. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the aflibercept-mrbb FDA label on DailyMed (effective October 27, 2025, Valorum Biologics, LLC); the BLA 761378 record on Drugs@FDA; every aflibercept-mrbb label on DailyMed.
Highlights of the record
FDA label of October 27, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageThese highlights do not include all the information needed to use AHZANTIVE safely and effectively.
Forms and strengths
- 40 mg/ml
Injection (solution).
On the market
- Earliest approval on file
- June 28, 2024 Ahzantive, Formycon Ag; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
What is aflibercept-mrbb used for?
From the label: indications and usageThese highlights do not include all the information needed to use AHZANTIVE safely and effectively. See full prescribing information for AHZANTIVE. Initial U.S. […]
FDA pharmacologic class: Vascular Endothelial Growth Factor Inhibitor.
Source: FDA drug label (AHZANTIVE), BLA761378 (Formycon Ag), as published by Valorum Biologics, LLC, effective October 27, 2025 (SPL set 289e4b90-f741-c0f6-e063-6394a90a2068), via openFDA; the full label on DailyMed
Is there a generic for aflibercept-mrbb (Ahzantive)?
No generic aflibercept-mrbb is approved (Drugs@FDA, October 8, 2026).
- 2024 earliest approval on file
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the aflibercept-mrbb label say about other medicines?
The aflibercept-mrbb label names 2 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Aflibercept | contraindications | Hypersensitivity AHZANTIVE is contraindicated in patients with known hypersensitivity to aflibercept or any of the excipients in AHZANTIVE. |
| Ranibizumab | warnings and precautions | The incidence of reported thromboembolic events in wet AMD studies during the first year was 1.8% (32 out of 1824) in the combined group of patients treated with aflibercept compared with 1.5% (9 out of 595) in patients treated with ranibizumab; … |
Source: FDA drug label (AHZANTIVE), BLA761378 (Formycon Ag), as published by Valorum Biologics, LLC, effective October 27, 2025 (SPL set 289e4b90-f741-c0f6-e063-6394a90a2068), via openFDA; the full label on DailyMed
What next?
- Other vascular endothelial growth factor inhibitors
- the pharmacologic class, with prices and generics
- Check an interaction
- what two or more labels say about each other